Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO Sells $116,521.74 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) CFO William J. Peters sold 4,231 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amphastar Pharmaceuticals Price Performance

AMPH traded up $0.49 on Friday, hitting $28.81. 544,259 shares of the company were exchanged, compared to its average volume of 589,149. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The business's fifty day moving average is $33.71 and its 200 day moving average is $41.93. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $26.98 and a fifty-two week high of $53.96. The firm has a market capitalization of $1.37 billion, a P/E ratio of 9.60, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77.

Analysts Set New Price Targets

Several brokerages have weighed in on AMPH. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 target price on the stock. Piper Sandler lowered shares of Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and lowered their target price for the stock from $66.00 to $36.00 in a research report on Tuesday, February 4th.

Remove Ads

Institutional Trading of Amphastar Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of AMPH. Pacer Advisors Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock valued at $50,139,000 after purchasing an additional 1,347,775 shares in the last quarter. Boston Trust Walden Corp lifted its holdings in shares of Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after purchasing an additional 439,281 shares in the last quarter. Boston Partners purchased a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at about $15,778,000. Wealthfront Advisers LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at about $9,268,000. Finally, Systematic Financial Management LP purchased a new position in shares of Amphastar Pharmaceuticals during the fourth quarter valued at approximately $9,147,000. Hedge funds and other institutional investors own 65.09% of the company's stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.